Intraprocedural Hemodynamics During Concomitant Rheocarna Therapy and Maintenance Hemodialysis: Effects of Dialyzer Membrane Type and Circuit Sequence.

J Clin ApherOct 1, 2026
Case ReportNephrologyVascular Surgery

Yusuke Ishizuka, Genshin Sato, Shizuka Ishigaki et al.

✦ AI-curated · Sources linked

Case in brief

Two patients with chronic limb-threatening ischemia (CLTI) undergoing maintenance hemodialysis received concomitant Rheocarna therapy. Each patient was treated with four configurations of dialyzer membranes and circuit sequences. The Rheocarna → AN69 configuration resulted in the least decrease in systolic blood pressure and better preservation of peripheral microvascular perfusion compared to other configurations, indicating improved hemodynamic stability during treatment.

Diagnostic / clinical pearl

The choice of dialyzer membrane type and circuit sequence can significantly impact hemodynamic stability during concomitant Rheocarna therapy and hemodialysis in patients with CLTI.

Why it matters

Understanding the effects of different treatment configurations may help optimize patient outcomes in those receiving combined therapies for CLTI.

Source

PubMed · PMID 42830539

Published in J Clin Apher. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.